HCMV

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, AIDS, Health, COVID-19, Infectious Diseases, Health Technology, Clinical Trials, Infection, Bangladesh Technical Education Board, RSV, CHB, Influenza, Peginterferon-alfa, HIV Vaccine Trials Network, GSK, Research, Investment, AASLD, HDV, MBA, Cirrhosis, HHS, Administration, Conditional sentence, Hepatology, RNA, Respiratory syncytial virus, ASPR, COVID, Patient, Family, HCMV, Bill, Development, HIV, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
  • The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01

Retrieved on: 
Thursday, December 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Vaccine, Infection, Safety, Ageing, Conditional sentence, Hepatitis, HCMV, Cancer, Birth

There is currently no approved vaccine against HCMV.

Key Points: 
  • There is currently no approved vaccine against HCMV.
  • The Phase I trial will be assessing safety and immunogenicity of the company’s HCMV vaccine in two different doses in healthy adults aged 18-50.
  • Target enrollment is approximately 120 participants and clinical data is expected in the first half of 2024.
  • “We see a great need for a vaccine against HCMV, as this virus causes thousands of permanent disabilities in newborns each year.

Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

Retrieved on: 
Wednesday, September 20, 2023
Vaccine, HIV/AIDS, Conditional sentence, Joint United Nations Programme on HIV/AIDS, HIV, Public, National Institute of Allergy and Infectious Diseases, Clinical trial, Research, Antibody, Bill & Melinda Gates Foundation, Person, Bangladesh Technical Education Board, Tuberculosis, Clinical research, Immune system, Bill, HVTN, HIV Vaccine Trials Network, NIAID, Health, HCMV, UNAIDS, Infection, Safety, Disease, Malaria, Pharmaceutical industry

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV). The Company expects initial data from the Phase 1 trial in the second half of 2024.

Key Points: 
  • The Company expects initial data from the Phase 1 trial in the second half of 2024.
  • VIR-1388 was developed using applied learnings from VIR-1111, the Company’s initial investigational proof-of-concept HIV T cell vaccine based on HCMV.
  • The Phase 1 trial of VIR-1388 will take place in both domestic and international sites within the federally funded HIV Vaccine Trials Network (HVTN) as study HVTN 142.
  • The randomized, double-blind, placebo-controlled Phase 1 trial (NCT05854381) is evaluating the safety, reactogenicity and immunogenicity of three different doses of VIR-1388 compared with placebo.

SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01

Retrieved on: 
Wednesday, September 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Vaccine, Health care, Conditional sentence, Clinical trial, Hepatitis, Cancer, CTA, Infection, HCMV, Birth, MHRA, Pharmaceutical industry

SpyBiotech , a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K.

Key Points: 
  • SpyBiotech , a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K.
  • Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate SPYVLP01, a vaccine targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology.
  • “Submission of our clinical trial application to evaluate SPYVLP01 marks important progress in the fight against the HCMV virus, a leading infectious cause of congenital abnormalities,” said Sumi Biswas, Ph.D., President and Chief Scientific Officer of SpyBiotech.
  • The first participant is expected to be dosed later this year with clinical data emerging in the first half of 2024.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Friday, August 4, 2023
Patent, Intellectual property, Inhalation, Australian patent law, Pathogenic bacteria, Conditioned place preference, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Coronavirus, COVID-19, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Biology, Ross River virus, Viral, Infection, Bacteria, Family, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
HIV Vaccine Trials Network, GSK, Corporate Affairs, EASL, Sotrovimab, HIV, Investment, Influenza, Marketing, Conference call, Head, Hook effect, National Institute of Allergy and Infectious Diseases, COVID-19, Hepatitis, PEG, CHB, MBA, Infection, Bill & Melinda Gates Foundation, Bangladesh Technical Education Board, JJI, Congress, Conditional sentence, Patient, Vir, SAN, HPV, Bill, European Association of Urology, AI, NIAID, Johnson & Johnson, Viral hepatitis, Vaccine, CHD, HCMV, Conference, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Management

ET, Aug. 3, 2023 –

Key Points: 
  • ET, Aug. 3, 2023 –
    SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • Vir expects the Phase 1 trial for VIR-1388, a novel T cell vaccine for the prevention of HIV, to begin dosing in Q3 2023.
  • In June, Sasha Damouni Ellis joined Vir as Executive Vice President and Chief Corporate Affairs Officer.
  • Revenues: Total revenues for the quarter ended June 30, 2023, were $3.8 million compared to $(40.6) million for the same period in 2022.

Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention

Retrieved on: 
Tuesday, May 2, 2023
HIV Vaccine Trials Network, Partnership, Biotechnology, Cytomegalovirus, HIV, Public, National Institute of Allergy and Infectious Diseases, Global health, Infection, Bangladesh Technical Education Board, Investment, Tuberculosis, SAN, HIV/AIDS, Epitope, Bill, HVTN, NIAID, Bill & Melinda Gates Foundation, HCMV, Malaria, Vaccine, Pharmaceutical industry

SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) --  Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it received a new $10 million grant from the Bill & Melinda Gates Foundation to support Vir’s novel T cell vaccine development program. The new grant will support the Phase 1 clinical development of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV). VIR-1388 is based on the human cytomegalovirus (HCMV) vector platform. Using applied learnings from VIR-1111, Vir’s initial investigational proof-of-concept HIV T cell vaccine, VIR-1388 is designed to elicit T cells that recognize different HIV epitopes with the goal of creating a safe and effective HIV vaccine. Through close scientific partnership with the National Institute of Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN), the Phase 1 trial of VIR-1388 (HVTN 142) is expected to begin in the second half of 2023. The trial will also be funded in part by NIAID, part of the National Institutes of Health, through grant funding to HVTN. NIAID has provided funding throughout the product development lifecycle of VIR-1388.

Key Points: 
  • The new grant will support the Phase 1 clinical development of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV).
  • Using applied learnings from VIR-1111, Vir’s initial investigational proof-of-concept HIV T cell vaccine, VIR-1388 is designed to elicit T cells that recognize different HIV epitopes with the goal of creating a safe and effective HIV vaccine.
  • “This new grant underscores the importance of our goal of developing innovative solutions for the prevention and treatment of global infectious diseases, including HIV.
  • HIV continues to be a major global public health challenge with no cure for the approximately 38 million people living with HIV infection.

Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Tuesday, April 11, 2023
Patent, Inhalation, Australian patent law, Veterans' Preference Act of 1944, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, Varicella zoster virus, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Patient, Biology, Ross River virus, Viral, Infection, Bacteria, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We would like to thank the Australian Patent Office for this notification of intent, which further validates the potential of our new class of anti-infectives to help patients with a broad range of bacterial and viral infections,” said James Graham, Chief Executive Officer of Recce Pharmaceutical.
  • Viral infections that may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), include herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome.